News

A Phase 3 clinical trial has been launched by MedDay Pharmaceuticals to investigate whether treatment with high-dose biotin (MD1003) may ease disability and improve mobility in non-relapsing primary or secondary progressive MS patients. The study is recruiting participants across the U.S., Canada and Europe. Biotin is a form of…

A clinical trial of a smartphone app that helps multiple sclerosis (MS) understand and manage their disease — and to aid and speed research — is now recruiting people nationwide. Claimed to be the first of its kind, the app, called myMS, is designed to give MS patients quick and easy access to pertinent information, from clinical evaluations…

Multiple sclerosis (MS) patients are largely moving away from injectable drugs and towards oral treatments when they switch from first to second-line MS therapies. But that might change with the introduction of Ocrevus (ocrelizumab), which has become the drug of choice for many neurologists advising patients on drug switches. The real-world analysis by…

A study of nearly 600 children with multiple sclerosis reported that genes linked to low vitamin D levels and obesity contribute to the risk of developing MS in childhood. While the two are also risk factors for adult-onset MS, obesity and low vitamin D have a larger risk impact on children than adults. The…

The online BrainHQ adaptive training program developed by Posit Science is better than any computer game at helping multiple sclerosis (MS) patients improve their cognitive skills, according to a study by researchers at New York University (NYU). The study, “Cognitive function in multiple sclerosis improves with telerehabilitation: Results from…

PODS (POlyhedrin Delivery System), a new technology designed to transport any protein in the human body, may open up new approaches in treating multiple sclerosis (MS) and other diseases, says its British developer, Cell Guidance Systems. Created by Hajime Mori, a professor at Japan’s Kyoto Institute of Technology, PODS is…

A large-scale study revealed potential adverse reactions to beta-interferon (IFN-β) therapy, one of the most common treatments used for relapsing-remitting multiple sclerosis (RRMS). According to the study published in the journal Neurology, patients have an increased risk of stroke, migraine, depression, and of developing abnormalities in the blood. In…

Two studies that recently appeared in the Multiple Sclerosis Journal shed light on how contraceptive use may affect women with MS, as well as how the disease might affect the safety and effectiveness of birth-control medications. Relapsing MS patients treated with older drugs such as interferons and Copaxone (glatiramer acetate) have a…

The expression by immune B-cells of a protein called T-bet is crucial to promoting production of autoantibodies that recognize and destroy the tissues of one’s own body, finds a new study by researchers at National Jewish Health in Denver. The study, “B cells expressing the transcription factor T-bet drive lupus-like autoimmunity,”…

Former Massachusetts First Lady Ann Romney, global ambassador for Boston’s Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, will deliver a keynote address at the Biotechnology Innovation Organization’s (BIO) International Convention in San Diego. Romney, who is scheduled to speak June 21, will talk about how her multiple sclerosis (MS)…

Recently approved, Ocrevus (ocrelizumab) should now be available nationwide for patients prescribed the therapy. But as with any new treatment, concerns about safety and practical issues are on many patients’ minds. Multiple Sclerosis News Today asked Dr. Jack Burks — a neurologist and researcher who serves as chief…

Loss of spinal cord neurons may not be a reliable tool to predict disability in patients with multiple sclerosis (MS), contrary to what was originally thought, according to researchers at Queen Mary University of London. Their study, “Axonal loss in the multiple sclerosis spinal cord revisited,” appeared in the journal…

The National Multiple Sclerosis Society is pumping $17 million into 43 research projects that represent almost half of its $40-million research funding commitment in 2017. Among the projects are trials evaluating intermittent fasting as a way to harness inflammation and stem cell research. A growing number of studies indicate that stem cells can slow…

The National Multiple Sclerosis Society (NMSS), together with its British partners, plans to launch a Phase 3 trial in the next few months to investigate whether simvastatin — a cheap drug that controls cholesterol levels — may be a suitable treatment for people with secondary progressive multiple sclerosis (SPMS). The trial,…

A variation in a gene that likely promoted resistance to malaria in Sardinia may have increased the risk of people there developing autoimmune diseases such as multiple sclerosis (MS) and systemic lupus erythematosus (SLE). The study, “Overexpression of the Cytokine BAFF and Autoimmunity Risk,” was published in The…

The risk of children developing multiple sclerosis (MS) later in life has no link to how much sunlight their mothers were exposed to during pregnancy, a Polish study found. The study, “Month of birth and level of insolation as risk factors for multiple sclerosis in Poland,” appeared in the journal…

Laquinimod failed to meet its primary Phase 3 clinical trial objective of slowing the progression of relapsing-remitting multiple sclerosis (RRMS) after three months, according to its developers, Teva Pharmaceutical Industries and Active Biotech. That has prompted the partners to abandon their quest to use the therapy to treat RRMS. Laquinimod…

A global Phase 3 clinical trial assessing MD1003 — also known as high-dose biotin — for progressive multiple sclerosis (MS) might lead to the approval of one of the first treatments helping select progressive patients to improve. The trial aims to prove that high-dose biotin can reverse disability in non-active progressive MS.

Babies of women with relapsing multiple sclerosis (RMS) who receive daily injections of Copaxone (glatiramer acetate) while pregnant carry the same risk of developing birth defects as babies as a whole, according to a study by the therapy’s developer, Teva Pharmaceutical Industries. The findings can help doctors counsel and treat…

People with multiple sclerosis (MS) and others with spinal cord injuries and disorders will speak at the United Spinal Association’s upcoming 6th Annual Roll on Capitol Hill, which takes place June 11-14 in Washington, D.C. Andrea Dalzell, Ms. Wheelchair New York 2015, will be among those advocating for greater access to complex rehabilitation technology.

A multiple sclerosis (MS) trial now underway in Colorado is assessing the safety and tolerability of switching from Rituxan (rituximab) to Ocrevus (ocrelizumab), and its lead investigator, Dr. Timothy L. Vollmer, largely expects no problems. The neurologist believes the two Genentech therapies — both antibody-based drugs that target the CD20 molecule on B-cells —…

The burden of moderate-to-severe relapses in multiple sclerosis (MS) patients is underappreciated, according to a study sponsored by the pharmaceutical company Mallinckrodt. Researchers discussed the findings at the American Academy of Neurology’s 69th annual meeting in Boston, April 22-28. The title of the presentation was “The Economic Burden Of…

Cladribine tablets reduce the risk of disability progression and relapse in patients with relapsing multiple sclerosis (MS), the CLARITY clinical trial indicates. The treatment was also well-tolerated and had a good safety profile, according to a presentation at the Annual Meeting of the American Academy of Neurology (AAN) in Boston,…

A cytomegalovirus infection triggers an increase in inflammatory and cytotoxic immune cells in mice with multiple sclerosis (MS), which leads to enhanced inflammation and loss of nerve-protecting myelin. The study, “Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation,” was published in the journal Scientific Reports. A cytomegalovirus (CMV) infection…

Axim Biotechnologies recently announced that its U.K. partner, Quay Pharmaceuticals, has secured licenses from the British Home Office to continue developing and importing its medical cannabinoid product MedChew Rx — a potential treatment for pain and spasticity in people with multiple sclerosis (MS), among other illnesses. MedChew Rx is a gum…

Smoking can kill off the immune cells that commonly protect people from multiple sclerosis (MS) and other autoimmune diseases, say researchers at the University of Copenhagen — a finding that may lead to new ways of treating such illnesses. Their study, “Smoking reduces circulating CD26hiCD161hi MAIT cells in healthy…

Neuroinflammation is an essential process in the development and progression of several neurodegenerative diseases, including multiple sclerosis (MS), Alzheimer’s and Parkinson’s. Researchers from the University of North Carolina School of Medicine have discovered that proteins known as NLRC4 and NLRP3 play key roles in regulating mechanisms involved in brain…

Although a Phase 2b trial of the remyelination drug candidate opicinumab (also known as anti-LINGO-1 and BIIB033) failed to meet its primary goal of improving disability in relapsing and secondary progressive multiple sclerosis (MS), researchers believe the drug did cause “fairly strong” improvements. The trial evaluated four doses of the…

Members of Parliament are helping the Multiple Sclerosis Society of Canada commemorate May as MS Awareness Month. The lawmakers will be meeting with society representatives and other members of the MS community in the capital of Ottawa, May 1-3. MS Awareness Month is a run-up to World MS Day on May…

The 31st Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) will take place May 24-27 at the Ernest N. Morial Convention Center in New Orleans. Typically hosting more than 2,000 attendees and 70 exhibitors, this event is the premier North American educational conference for international clinicians and scientists…